Anthony El-Khoueiry

14PUBLICATIONS
145CO-AUTHORS
Molecular targetsInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Dec 03, 2025
Outcomes of Patients With Solid Tumor Treated on Phase I Clinical Trials Within a Comprehensive Cancer Center's Private and Safety-Net Hospitals.

Jacob Stephen Thomas, Gage Guerra, Sabrina Woll

|Sep 30, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

James J Harding, Do-Youn Oh, Teresa Macarulla Mercade

|Jan 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.

Breelyn A Wilky, Gary K Schwartz, Michael S Gordon

|Jan 23, 2025
First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors.

Anthony El-Khoueiry, Omar Saavedra, Jacob Thomas

|Dec 13, 2024
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.

Rachna T Shroff, Gentry King, Sarah Colby

|Oct 18, 2024
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial.

Teresa Macarulla, Zhenggang Ren, Hong Jae Chon

Pageof 3

Frequent Collaborators

3 joint publications

Rachna T Shroff

2 joint publications

Nilofer S Azad

2 joint publications

Mitesh J Borad

2 joint publications

Joon Oh Park